Background: Industry funding has been associated with favourable trial outcomes across several areas of medicine, but whether this association exists in arterial vascular surgery is unclear. We evaluated the association between industry sponsorship and reported primary outcome direction in major arterial vascular randomised controlled trials.Methods: We conducted a cross-sectional meta-research analysis of 60 arterial vascular randomised controlled trials meeting predefined eligibility criteria. Extracted variables included funding source; trial design; non-inferiority margin reporting; and primary outcome direction. Fisher's exact testing and logistic regression were used to evaluate the association between industry sponsorship and the likelihood of a positive primary outcome. A positive outcome was prespecified as superiority or non-inferiority of the newer or higher-cost intervention compared with the control, according to the stated trial design.Findings: Of 60 randomised trials included, 59 contributed to the primary outcome analysis, comprising 32 industry-funded, 22 non-industry-funded, three mixed-funded and two trials with unknown funding. Industry-funded trials were more likely to report positive primary outcomes than all other trials (78% vs 26%; Fisher's exact test: OR 9.7, 95% CI 2.68–41; p<0.001). Logistic regression demonstrated similar findings (OR 10.2, 95% CI 3.24–36; p<0.001). The association remained consistent in sensitivity analyses excluding studies with mixed and unknown funding status. Among seven non-inferiority trials, three of five industry-funded trials reported a predefined numerical non-inferiority margin before trial commencement, whereas both the non-industry-funded and mixed-funded non-inferiority trials reported predefined margins.Interpretation: Industry sponsorship was strongly associated with favourable primary outcomes in arterial vascular randomised controlled trials. Although the mechanisms underlying this association cannot be determined from this study, the findings support greater transparency in trial funding, prospective reporting of non-inferiority methodology and independent methodological oversight to strengthen the integrity, reproducibility and interpretation of the arterial vascular evidence base.